BIOGEN INC. is 1.6x more valuable than Moderna, Inc. by market capitalization ($28.73 B vs $18.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MRNA | BIIB |
|---|---|---|
| Market cap | $18.25 B | $28.73 B |
| US-listed rank | #650 | #479 |
| Revenue (latest FY) | $1.94B | $9.89B |
| Net income (latest FY) | -$2.82B | $1.29B |
| Net margin | -145.2% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 1,447 | 2,690 |
BIOGEN INC. is 1.6x more valuable than Moderna, Inc. by market capitalization ($28.73 B vs $18.25 B).
In their latest fiscal years, Moderna, Inc. reported $1.94B in revenue while BIOGEN INC. reported $9.89B.
Full pages: Moderna, Inc. and BIOGEN INC., or browse the full rankings.